Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma
{{output}}
Glioblastoma is the most aggressive and most common grade 4 tumor of the central nervous system (CNS). Despite standard treatments such as surgical resection and chemoradiotherapy, overall survival (OS) usually does not exceed 14-16 months in clinical trials, ... ...
